Bionano Genomics (BNGO) stock surged 7.64% in the pre-market session on Monday.
The rally comes after the company announced positive results from a study at Johns Hopkins University School of Medicine, showing that its Optical Genome Mapping (OGM) technology outperformed multiple cytogenetic assays in the analysis of bone and soft tissue tumors. Key findings included: - OGM detected 100% of variants found by standard techniques like karyotyping and FISH - OGM was more sensitive, detecting diagnostic variants missed by karyotyping in 74% of failed/negative cases - Combined with next-generation sequencing, OGM found diagnostic variants in ~98% of cases, substantially higher than standard methods The researchers highlighted OGM's potential to qualify more patients for targeted therapies or clinical trials based on the additional variants detected.
The positive study results suggest increasing adoption potential for Bionano's OGM technology beyond blood cancers into solid tumor analysis as well.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。